Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023

Rhea-AI Summary

Novavax, Inc. (NASDAQ: NVAX) will release its fourth quarter and full-year 2022 financial results on February 28, 2023, at 4:30 p.m. EST. The call will discuss operational highlights and include a Q&A session. Participants are encouraged to join early and can access the call through a webcast. A replay will be available from 7:30 p.m. EST on the same day until March 7, 2023. Novavax focuses on developing innovative vaccines for serious infectious diseases, enhancing vaccine efficacy through its patented Matrix-M adjuvant technology.

Positive

• Upcoming earnings report may provide insights into revenue and operational performance.
• Focus on advanced protein-based vaccines could enhance market positioning.

Negative

• None.

GAITHERSBURG, Md., Feb. 21, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets. Details of the event and replay are as follows:

Conference call details:
Date:	February 28, 2023
Time:	4:30 p.m. U.S. Eastern Standard Time (EST)
Dial-in number:	(833) 974-2381 (Domestic) or (412) 317-5774 (International)
Webcast:	ir.novavax.com/events

• Participants will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

Replay details:
Date:	Available starting at 7:30 p.m. EST, February 28, 2023 until 11:59 p.m. U.S. EST, March 7, 2023
Dial-in number:	(877) 344-7529 (Domestic) or (412) 317-0088 (International)
Passcode:	1137418
Webcast:	ir.novavax.com/events, until May 28, 2023

About Novavax  
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.

CONTACTS   
Investors   
Erika Schultz  
240-268-2022  
ir@novavax.com

Media   
Ali Chartan  
240-720-7804  
media@novavax.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2022-financial-results-and-operational-highlights-on-february-28-2023-301751345.html

SOURCE Novavax, Inc.

FAQ

When will Novavax report its fourth quarter 2022 results?

Novavax will report its fourth quarter 2022 results on February 28, 2023.

What time is the Novavax earnings call scheduled for?

The earnings call is scheduled for 4:30 p.m. EST on February 28, 2023.

How can I access the Novavax earnings call?

The Novavax earnings call can be accessed by dialing (833) 974-2381 for domestic or (412) 317-5774 for international callers.

Is there a replay available for the Novavax earnings call?

Yes, a replay will be available starting at 7:30 p.m. EST on February 28, 2023, until March 7, 2023.

What is Novavax's focus in vaccine development?

Novavax is focused on developing innovative vaccines for COVID-19, influenza, and other serious infectious diseases.